Literature DB >> 32584153

Do repeated transurethral procedures under general anesthesia influence mortality in patients with non-invasive urothelial bladder cancer? A Danish national cohort study.

Marie Schmidt Erikson1, Astrid Christine Petersen2, Klaus Kaae Andersen3, Frederik Krogsdal Jacobsen3, Karin Mogensen1, Gregers Gautier Hermann1.   

Abstract

Purpose: To investigate the effect of repeated transurethral procedures under general anesthesia on overall mortality in patients with non-invasive bladder cancer.Materials and methods: All Danish residents with non-invasive papillary urothelial carcinoma or primary urothelial carcinoma in situ diagnosed between 1 January 2000 and 1 January 2011 were included and followed until death or 31 March 2017. All transurethral procedures under general anesthesia, intravesical instillation therapy, recurrences and progression to invasive disease or cystectomy were recorded during follow-up. Associations between treatments and overall mortality were evaluated using multivariable regression analysis adjusted for age, gender, comorbidities and socioeconomic status. The effect of disease progression on mortality was removed by censoring patients at the time of progression or cystectomy.
Results: Risk of death increased with the number of transurethral procedures under general anesthesia for Ta low- and high-grade tumors compared to patients who had only one procedure; after eight or more procedures the risk of death increased by 28% and 83%, respectively. There was no similar relationship for carcinomas in situ. In total, 36-52% of procedures under general anesthesia did not identify urothelial neoplasia.Conclusions: Repeated transurethral procedures under general anesthesia appear to be associated with increased risk of death in patients with primary non-invasive papillary urothelial carcinoma. Furthermore, a substantial number of procedures were without findings of neoplasia, indicating that too many patients are admitted for transurethral procedures under GA. Attempts should be taken to reduce unnecessary transurethral procedures under GA, e.g. by improved outpatient diagnosis of urothelial neoplasia.

Entities:  

Keywords:  NMIBC; Non-invasive bladder cancer; TUR-BT; mortality; progression; recurrence

Mesh:

Year:  2020        PMID: 32584153     DOI: 10.1080/21681805.2020.1782978

Source DB:  PubMed          Journal:  Scand J Urol        ISSN: 2168-1805            Impact factor:   1.612


  2 in total

1.  Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial.

Authors:  K Kent Chevli; Neal D Shore; Andrew Trainer; Angela B Smith; Daniel Saltzstein; Yaron Ehrlich; Jay D Raman; Boris Friedman; Richard D'Anna; David Morris; Brian Hu; Mark Tyson; Alexander Sankin; Max Kates; Jennifer Linehan; Douglas Scherr; Steven Kester; Michael Verni; Karim Chamie; Lawrence Karsh; Arnold Cinman; Andrew Meads; Soumi Lahiri; Madlen Malinowski; Nimrod Gabai; Sunil Raju; Mark Schoenberg; Elyse Seltzer; William C Huang
Journal:  J Urol       Date:  2021-08-26       Impact factor: 7.450

2.  Number of transurethral procedures after non-muscle-invasive bladder cancer and survival in causes other than bladder cancer.

Authors:  Lars Holmberg; Oskar Hagberg; Christel Häggström; Truls Gårdmark; Viveka Ströck; Firas Aljabery; Staffan Jahnson; Abolfazl Hosseini; Tomas Jerlström; Amir Sherif; Karin Söderkvist; Anders Ullén; Mats Enlund; Fredrik Liedberg; Per-Uno Malmström
Journal:  PLoS One       Date:  2022-09-23       Impact factor: 3.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.